[
  {
    "ts": "2026-02-13T12:42:14+00:00",
    "headline": "Novocure’s stock rises 37% on FDA clearance of pancreatic cancer treatment device",
    "summary": "Novocure’s Optune Pax delivers electric tumour treating fields (TTFields), targeting the electrical properties of cancer cells to thwart their survival and division.",
    "url": "https://www.medicaldevice-network.com/news/novocure-stock-rises-37-on-fda-clearance-of-pancreatic-cancer-treatment-device/",
    "source": "Medical Device Network",
    "provider": "yfinance",
    "raw": {
      "id": "9294f718-207a-3206-8ae9-b963bd9b15bb",
      "content": {
        "id": "9294f718-207a-3206-8ae9-b963bd9b15bb",
        "contentType": "STORY",
        "title": "Novocure’s stock rises 37% on FDA clearance of pancreatic cancer treatment device",
        "description": "",
        "summary": "Novocure’s Optune Pax delivers electric tumour treating fields (TTFields), targeting the electrical properties of cancer cells to thwart their survival and division.",
        "pubDate": "2026-02-13T12:42:14Z",
        "displayTime": "2026-02-13T12:42:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/medical_device_network_744/47ce25ff087dc098b12a2ae98de8fbd8",
          "originalWidth": 1440,
          "originalHeight": 810,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/N2CSixWLULrZP9LciEdz1w--~B/aD04MTA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/medical_device_network_744/47ce25ff087dc098b12a2ae98de8fbd8.cf.webp",
              "width": 1440,
              "height": 810,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/p6tWyqfUhuRd5_mDiaIBzQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/medical_device_network_744/47ce25ff087dc098b12a2ae98de8fbd8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Medical Device Network",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.medicaldevice-network.com/news/novocure-stock-rises-37-on-fda-clearance-of-pancreatic-cancer-treatment-device/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novocure-stock-rises-37-fda-124214725.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVCR"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T12:13:52+00:00",
    "headline": "Eli Lilly Expands Beyond GLP 1 With Cell And Genetic Therapies",
    "summary": "Eli Lilly (NYSE:LLY) announced an agreement to acquire Orna Therapeutics for up to $2.4b, adding circular RNA and in vivo CAR T technology to its drug development toolkit. The company also expanded its partnership with Innovent Biologics to work on new immunology and oncology treatments. These moves push Lilly further into cell and genetic therapies beyond its established diabetes and obesity drug portfolio. Eli Lilly enters this set of deals with a market profile shaped by a very large 3...",
    "url": "https://finance.yahoo.com/news/eli-lilly-expands-beyond-glp-121352404.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "2d0db039-e2d5-3a4f-97b2-0483c9298c82",
      "content": {
        "id": "2d0db039-e2d5-3a4f-97b2-0483c9298c82",
        "contentType": "STORY",
        "title": "Eli Lilly Expands Beyond GLP 1 With Cell And Genetic Therapies",
        "description": "",
        "summary": "Eli Lilly (NYSE:LLY) announced an agreement to acquire Orna Therapeutics for up to $2.4b, adding circular RNA and in vivo CAR T technology to its drug development toolkit. The company also expanded its partnership with Innovent Biologics to work on new immunology and oncology treatments. These moves push Lilly further into cell and genetic therapies beyond its established diabetes and obesity drug portfolio. Eli Lilly enters this set of deals with a market profile shaped by a very large 3...",
        "pubDate": "2026-02-13T12:13:52Z",
        "displayTime": "2026-02-13T12:13:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-expands-beyond-glp-121352404.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-expands-beyond-glp-121352404.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "IVBIY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T11:21:51+00:00",
    "headline": "Analysis-US could take action including fines against Hims after brief Wegovy copy launch",
    "summary": "WASHINGTON, Feb 13 (Reuters) - The Trump administration could take action including an injunction or fines against online telehealth company Hims for intending to sell a compounded version of Novo Nordisk's Wegovy weight-loss pill, though its legal options may be curbed by Hims' quick retreat, ‌attorneys and other experts told Reuters. Hims and Hers Health last week said it would offer a much cheaper $49 version of Novo Nordisk's Wegovy weight-loss pill, before ‌backing off the plan after the F",
    "url": "https://finance.yahoo.com/news/analysis-us-could-action-including-110506676.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "db7f77ae-17ba-3819-9d72-c8dd30ccbc8f",
      "content": {
        "id": "db7f77ae-17ba-3819-9d72-c8dd30ccbc8f",
        "contentType": "STORY",
        "title": "Analysis-US could take action including fines against Hims after brief Wegovy copy launch",
        "description": "",
        "summary": "WASHINGTON, Feb 13 (Reuters) - The Trump administration could take action including an injunction or fines against online telehealth company Hims for intending to sell a compounded version of Novo Nordisk's Wegovy weight-loss pill, though its legal options may be curbed by Hims' quick retreat, ‌attorneys and other experts told Reuters. Hims and Hers Health last week said it would offer a much cheaper $49 version of Novo Nordisk's Wegovy weight-loss pill, before ‌backing off the plan after the F",
        "pubDate": "2026-02-13T11:21:51Z",
        "displayTime": "2026-02-13T11:21:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/34db269823393a0d4055ae912a981c84",
          "originalWidth": 800,
          "originalHeight": 526,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J46cHXFeiV.KCDB1bvBXnw--~B/aD01MjY7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/34db269823393a0d4055ae912a981c84.cf.webp",
              "width": 800,
              "height": 526,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/M5ZSOeqVBAjq_1jRNkUlxw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/34db269823393a0d4055ae912a981c84.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/analysis-us-could-action-including-110506676.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysis-us-could-action-including-110506676.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T14:24:00+00:00",
    "headline": "Elanco Announces Updates to Board of Directors",
    "summary": "Elanco Animal Health Incorporated (NYSE: ELAN) today announced updates to its Board of Directors. R. David Hoover and Deborah Kochevar will not stand for re-election at the conclusion of their terms at the 2026 Annual Meeting of Shareholders in May.",
    "url": "https://finance.yahoo.com/news/elanco-announces-updates-board-directors-142400658.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "b32b295d-f602-3378-b2eb-67620a28f444",
      "content": {
        "id": "b32b295d-f602-3378-b2eb-67620a28f444",
        "contentType": "STORY",
        "title": "Elanco Announces Updates to Board of Directors",
        "description": "",
        "summary": "Elanco Animal Health Incorporated (NYSE: ELAN) today announced updates to its Board of Directors. R. David Hoover and Deborah Kochevar will not stand for re-election at the conclusion of their terms at the 2026 Annual Meeting of Shareholders in May.",
        "pubDate": "2026-02-13T14:24:00Z",
        "displayTime": "2026-02-13T14:24:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/a311ae0d2c70e9652fafd66dc89a71d7",
          "originalWidth": 400,
          "originalHeight": 267,
          "caption": "Elanco logo (PRNewsfoto/Elanco Animal Health)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YVlah8Of7uCdH0.E7W3ozw--~B/aD0yNjc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a311ae0d2c70e9652fafd66dc89a71d7.cf.webp",
              "width": 400,
              "height": 267,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jQVWGyXDrcoazxzeSZz1MA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a311ae0d2c70e9652fafd66dc89a71d7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/elanco-announces-updates-board-directors-142400658.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/elanco-announces-updates-board-directors-142400658.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ELAN"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]